Past Coverage of EULAR 2016Past Coverage of EULAR 2016 Return To RheumReports Home
One size (questionnaire) fits all? RAPID3 in PsA
June 9 2016 10:48 PM ET — via RheumReports
RAPID3 is a questionnaire consisting of the HAQ and two visual analog scales (VAS) that has been validated in RA. If it performs well in PsA, it could be used as a generic assessment tool for evaluation of most peripheral inflammatory arthritis managed by rheumatologists.
Coates et al. (#THU0419) evaluated the responsiveness and discrimination of RAPID3 and a modified version with skin VAS (RAPID3Ps) in the Tight Control of Psoriatic Arthritis (TICOPA) trial.
RAPID3 and RAPID3Ps scores strongly correlated with PASDAS at all baseline and follow-up visits. The change in score at follow-up was also moderately correlated with the change in PASDAS.
RAPID3 score showed strong discriminant ability between the two treatment arms (tight control and standard care) in the TICOPA trial and performed better than measures (including MD Global, Patient Global, pain VAS, DAPSA, fatigue, TJC and SJC) except for PASDAS.
RAPID3 "near remission" was also highly discriminant between treatment groups, but not better than the MDA criteria. The addition of the psoriasis VAS (RAPID3Ps) did not provide additional benefit.
Thus, RAPID3 may be useful as a patient-reported composite outcome measure for PsA.
Share This Report
About the Author
Dr. Vinod Chandran
Dr. Chandran is a rheumatologist and clinician-scientist, an Assistant Professor of Medicine & Laboratory Medicine and Pathobiology at the University of Toronto, an affiliate scientist at the Krembil Research Institute, a staff physician at the University Health Network and Mount Sinai Hospitals, and an associate member of the graduate faculty at the Institute of Medical Science. He co-directs the Psoriatic Arthritis Program at the University Health Network.
View Full Bio